AIDS 2022: the agency takes part in the conference dedicated to HIV
The ANRS | Emerging Infectious Diseases is participating in the International AIDS Society (IAS) AIDS Conference in Montreal from July 29 to August 2, 2022. In addition to partnering with the event, the agency is organizing a symposium, awards six prizes to young researchers and having the work it supports presented during the scientific sessions.
The AIDS conference, organized every two years by the IAS, brings together thousands of researchers from all continents to assess progress made on HIV/AIDS. This year, for the 24th edition, the theme is "re-engage and follow the science". The event is held in Montreal and in virtual format. The ANRS | Emerging Infectious Diseases is committed to carry on its involvement in this major international event.
The agency is organizing a satellite symposium on community-based research, bringing together international experts, researchers and association representatives.
- Friday, July 29th, 2022 from 1:00 p.m. to 2:30 p.m. (Montreal time) / from 7:00 p.m. to 8:30 p.m. (Paris time) - Room 517c / Channel 5
Find out more about the program: https://www.anrs.fr/en/actualites/1108/aids-2022-agency-hosts-symposium-community-based-research
A thematic folder is availaible here: https://www.anrs.fr/sites/default/files/2022-07/Press_kit_community_based_research_vdef.pdf
The replay will be availaible following the event.
The France stand highlights the country’s commitment to the fight against HIV. The CRIPS Île-de-France, the Ministry of Europe and Foreign Affairs, the Ministry of Health and Prevention, the DGS, Expertise France and the ANRS | Emerging Infectious Diseases are the funders.
Several meetings are planned. Among them, a meeting between the Ministry of Europe and Foreign Affairs, the GHA, Unitaid and the agency will be held on the theme "universal access to health innovations / health a global good?" from 3:00 to 4:00 p.m. (Montreal time), on July 31.
A discussion on "3x95: what solutions to reach the first 95?" is also scheduled for August 1 from 3:00 to 4:00 p.m. (Montreal time).
Meet us in the exhibition area, booth 1010 (level 2).
Pr Yazdan Yazdanpanah is participating in two sessions:
- "How does implementation science affect HIV policy and vice versa?" July 29th between 11:45 a.m. to 12:45 a.m. (Montreal time) / 5:45 p.m. to 6:45 (Paris time) – Room 510 or channel 8: https://programme.aids2022.org/Programme/Session/90
- The symposium : "Treatment Optimisation: Lessons from ADVANCE, DolPHIN 2 and NAMSAL trials" with Mireille MPoudi NGole-Etame from the ANRS partner site in Cameroon, July 30, 8:00-9:00 a.m. (Montreal time) / 2:00-3:00 p.m. (Paris time) – room 517b or channel 4: https://programme.aids2022.org/Programme/Session/194
Jacqueline Capeau will speak at the symposium "Metabolic consequences of new classes of ART" on July 30 from 10:30 to 11:30 a.m. (Montreal time) / 4:30 to 5:30 p.m. (Paris time) – Room 510 or channel 8: https://programme.aids2022.org/Programme/Session/23
Asier Sáez-Cirión (Institut Pasteur), co-coordinator of the ANRS RHIVIERA consortium, will participate in the symposium "Combinations to reprogram CD8+ T cells" on July 31 from 2:15 to 3:15 p.m. (Montreal time) / 8:15 to 9:45 p.m. (Paris time) – Room 517d or channel 2: https://programme.aids2022.org/Programme/Session/17
Sharon Lewin, Director of the Peter Doherty Institute for Infection and Immunity and Chair of the Agency's Scientific Advisory Board, will speak at the closing session of the conference on August 2 from 4:45-5:30 p.m. (Montreal time) / 10:45-11:30 p.m. (Paris time) – Room 220 d/e channel 1: https://programme.aids2022.org/Programme/Session/78
The six IAS/ANRS Lange/van Tongeren reward young researchers whose work on HIV are innovative, original and of high quality in each of the event's scientific categories. Winners receive a prize of US$2,000, awarded jointly by the IAS and the agency.
- Tuesday, August 2, 10:10 a.m. (Montreal time) / 4:10 p.m. (Paris time) – Room 220 d/e channel 1: https://programme.aids2022.org/Programme/Session/81
This year again, research supported by the agency has been selected by the IAS to be presented during the scientific sessions.
|Presenter||Type of présentation||Title||Link to the program|
|Mireille Mpoudi-Etame||oral abstract||Dolutegravir versus Efavirenz-400 as first-line ART in Cameroon: Week 192 data of NAMSAL trial||Lien
|Basma Abdi||e-poster||Seroprevalence of SARS-CoV-2 infection and evolution of humoral response in PLWHIV||Link|
|Maryam Bendoumou||e-poster||Role of UHRF1 in HIV-1 transcriptional regulation||Link|
|Alexandra Bitty-Anderson||e-poster||Low awareness of pre-exposure prophylaxis among female sex workers in Togo||Link|
|Lucy Kundura||Poster exhibition||Low frequency of activated T cells in people living with HIV, aviremic under treatment, and presenting neurocognitive disorders||Link|
|Pierre Debeaudrap||e-poster||Evaluation of screening algorithms based on HPV testing with partial genotyping for the prevention of cervical cancer among HIV-infected women in resource-limited countries: results of the ANRS 12375 study||Link|
|August Eubanks||e-poster||Socio-behavioral correlates of PrEP uptake and correct PrEP adherence in men who have sex with men in West Africa (CohMSM-PrEP ' ANRS12369 ' Expertise France)||Link|
|Inès Dourado||e-poster||SARS-CoV-2 antibodies prevalence among sexual and gender minorities youth in Brazil||Link|
Factors associated with HIV transmission risk from men who have sex with men to women in West Africa (CohMSM ANRS 12324-Expertise France)
|Vincent Cantaloube-Ferrieu||e-poster||Barriers that limit cell-free HIV-1 entry into macrophages are overcome after cell-cell fusion with infected T cells||Link|
|Marcellin Nouaman||e-poster||Prevalence and incidence of sexually transmitted infections in a cohort of female sex workers in San Pedro, Côte d'Ivoire (ANRS 12381 PRINCESSE)||Link|
|Joseph Larmarange||e-poster||Delays to PrEP initiation among female sex workers in Côte d’Ivoire (ANRS 12381 PRINCESSE project)||Link|
|Celso Khosa||e-poster||Incidence and risk factors for liver enzyme elevation in HIV-1 infected patients treated for tuberculosis: a secondary analysis of the multi-country ANRS 12300 REFLATE TB2 trial||Link|
|Dominique Costagliola||e-poster||Projection of age of people living with HIV and time since ART initiation in high-income countries in 2030: estimates for France||Link|
|Delphine Planas||e-poster||Side-by-side comparison of SARS-CoV-2 neutralizing antibody responses after various COVID-19 vaccine regimens||Link|
|Perrine Roux||e-poster||Characteristics of chemsexers in France during the COVID-19 pandemic: results from the ERAS 2021 national online survey||Link|
|Perrine Roux||e-poster||The positive impact of drug consumption rooms on HIV/HCV risk practices among people who inject drugs: results from the COSINUS cohort study||Link|
|Carine Van Lint||e-poster||Role of the polgene enhancer in HIV-1 transcription and replication in myeloid infected cells||
|Leslie Alcouffe||e-poster||Sexual health of migrant women attending French Red Cross Health Prevention Centers in French Guiana, in 2021||Link|
Knowledge of HIV pre-exposure prophylaxis and antiretrovirals preventive potential of among migrant women in French Guiana
|Diogo Gama Caetano||e-poster||Alterations in B lymphocyte subsets in virologically suppressed HIV-positive individuals did not impact 17DD yellow fever vaccine immunogenicity - ANRS 12403||Link|